The observation that PD-L1 overexpression is more prevalent among BAA patients suggested that racial background could influence immune suppression during pancreatic cancer progression, which may lead to variations in responses to immunotherapy across different races. This evidence concerns the gene CD274 and familial pancreatic carcinoma.